Group 1 - The core point of the article is that LuKang Pharmaceutical plans to increase the registered capital of its wholly-owned subsidiaries, aiming to strengthen its agricultural pesticide and sales sectors to meet business expansion needs [1] - LuKang Pharmaceutical will increase the registered capital of Shandong LuKang Biological Pesticide Co., Ltd. from 41.25 million yuan to 150 million yuan, and Shandong LuKang Zerun Pharmaceutical Co., Ltd. from 3 million yuan to 30 million yuan [1] - The revenue composition for LuKang Pharmaceutical in 2024 is projected to be 54.29% from human antibiotics, 39.72% from veterinary antibiotics, 4.89% from other sources, and 1.1% from other businesses [1] - As of the report date, LuKang Pharmaceutical has a market capitalization of 8.4 billion yuan [1]

Company Overview - Lu Kang Pharmaceutical (SH 600789) announced a temporary board meeting on September 19, 2025, to review the mid-term adjustments to the 2025 investment plan [1] - As of the report, Lu Kang Pharmaceutical has a market capitalization of 8.9 billion yuan [1] Revenue Composition - For the year 2024, the revenue composition of Lu Kang Pharmaceutical is as follows: - Human antibiotics account for 54.29% - Veterinary antibiotics account for 39.72% - Other businesses account for 4.89% - Additional business activities account for 1.1% [1]